<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11386780
   </pmid>
   <datecreated>
    <year>
     2001
    </year>
    <month>
     06
    </month>
    <day>
     01
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2001
    </year>
    <month>
     08
    </month>
    <day>
     09
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     06
    </month>
    <day>
     08
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0266-7681
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       26
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2001
       </year>
       <month>
        Jun
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of hand surgery (Edinburgh, Scotland)
     </title>
     <isoabbreviation>
      J Hand Surg Br
     </isoabbreviation>
    </journal>
    <articletitle>
     Treatment of de Quervain's disease:role of conservative management.
    </articletitle>
    <pagination>
     <medlinepgn>
      258-60
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      This retrospective study compares two methods used to treat de Quervain's disease: splintage with oral non-steroidal anti-inflammatory drugs (NSAIDs) and steroid injection. Patients were separated into three groups based on symptom severity: group I-minimal, group II-mild, and group III-moderate or severe. Three hundred and nineteen wrists in 300 patients were followed from one to six years. Fifteen of 17 patients with minimal symptoms were relieved with splintage and NSAIDs. However, only seven of 20 in Group II and two of eight in Group III treated similarly were relieved. Of the 249 patients in Group III treated with injections, 76% were completely relieved, 7% were improved, and 4% were not improved. We conclude that classification of patients' with de Quervain's disease based on their pre-treatment symptoms may assist surgeons in selecting the most efficacious treatment and in providing prognostic information to their patients.
     </abstracttext>
     <copyrightinformation>
      Copyright 2001 The British Society for Surgery of the Hand.
     </copyrightinformation>
    </abstract>
    <affiliation>
     Department of Orthopaedic Surgery, Albert Einstein College of Medicine of Yeshiva University, New York, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Lane
      </lastname>
      <forename>
       L B
      </forename>
      <initials>
       LB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Boretz
      </lastname>
      <forename>
       R S
      </forename>
      <initials>
       RS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Stuchin
      </lastname>
      <forename>
       S A
      </forename>
      <initials>
       SA
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     Scotland
    </country>
    <medlineta>
     J Hand Surg Br
    </medlineta>
    <nlmuniqueid>
     8403839
    </nlmuniqueid>
    <issnlinking>
     0266-7681
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      22204-53-1
     </registrynumber>
     <nameofsubstance>
      Naproxen
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      378-44-9
     </registrynumber>
     <nameofsubstance>
      Betamethasone
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      52081-45-5
     </registrynumber>
     <nameofsubstance>
      betamethasone acetate phosphate
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Oral
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged, 80 and over
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Betamethasone
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Combined Modality Therapy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Injections, Intra-Articular
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Naproxen
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Retrospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Splints
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tenosynovitis
     </descriptorname>
     <qualifiername majortopicyn="N">
      classification
     </qualifiername>
     <qualifiername majortopicyn="Y">
      rehabilitation
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2001
     </year>
     <month>
      6
     </month>
     <day>
      2
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2001
     </year>
     <month>
      8
     </month>
     <day>
      10
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2001
     </year>
     <month>
      6
     </month>
     <day>
      2
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11386780
    </articleid>
    <articleid idtype="doi">
     10.1054/jhsb.2001.0568
    </articleid>
    <articleid idtype="pii">
     S0266-7681(01)90568-6
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

